Phreesia (PHR)
(Delayed Data from NYSE)
$18.92 USD
-2.39 (-11.22%)
Updated May 31, 2024 03:59 PM ET
After-Market: $18.91 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
Phreesia, Inc. [PHR]
Reports for Purchase
Showing records 1 - 20 ( 169 total )
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Profits Cash Generation Clearly in Focus; See Pathway to Consistent 15%+ Growth at MSD Margins
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Phreesia, Inc.
Industry: Medical Info Systems
Top- and Bottom-Line Beat; Pushes Out Initial FY25 Revenue Guidance to FY26
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Proprietary Healthcare - Credit Card Transaction Data
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Company: Phreesia, Inc.
Industry: Medical Info Systems
Continue to Like the 2H + FY25 Setup on Multi-Pronged Platform with Growth from Higher-Margin Contributions; Remain OW
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Phreesia, Inc.
Industry: Medical Info Systems
Bottom-Line Beat with Network Solutions Not Seeing Slowdown as We Expected; FY Revenue Guidance Maintained, but Adjusted EBITDA Raised by ~10%
Provider: KeyBanc Capital Markets
Analyst: Research Department